NASDAQ:VCELVericel Stock Price, Forecast & News

Vericel's stock was trading at $12.08 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, VCEL shares have increased by 42.3% and is now trading at $17.19.
View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vericel in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Vericel.

Vericel is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020.
View our earnings forecast for Vericel.

Vericel will be holding an earnings conference call on Wednesday, August 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Vericel Corp (NASDAQ:VCEL) announced its quarterly earnings data on Tuesday, May, 5th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by $0.02. The biotechnology company had revenue of $26.70 million for the quarter, compared to analyst estimates of $26.23 million. Vericel had a negative net margin of 9.39% and a positive return on equity of 5.87%. Vericel's revenue was up 22.5% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.07) earnings per share.
View Vericel's earnings history.

Vericel updated its second quarter 2020 Pre-Market earnings guidance on Thursday, July, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $20-20 million, compared to the consensus revenue estimate of $15.79 million.

5 analysts have issued 1-year price targets for Vericel's shares. Their forecasts range from $21.00 to $32.00. On average, they expect Vericel's stock price to reach $24.25 in the next twelve months. This suggests a possible upside of 41.1% from the stock's current price.
View analysts' price targets for Vericel.

Media coverage about VCEL stock has been trending somewhat positive on Monday, according to InfoTrie Sentiment. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Vericel earned a news impact score of 1.6 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future.
View the latest news about Vericel.

Some companies that are related to Vericel include Denali Therapeutics (DNLI), Fate Therapeutics (FATE), Twist Bioscience (TWST), Sorrento Therapeutics (SRNE), Immunovant (IMVT), SpringWorks Therapeutics (SWTX), Editas Medicine (EDIT), Legend Biotech (PCVX), Sangamo Therapeutics (SGMO), Mesoblast (MESO), Bill.com (RVMD), Adverum Biotechnologies (ADVM), NanoString Technologies (NSTG), Forma Therapeutics (FMTX) and Coherus Biosciences (CHRS).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Vericel investors own include Exelixis (EXEL), Momo (MOMO), Novavax (NVAX), Amarin (AMRN), Synergy Pharmaceuticals (SGYP), Dynavax Technologies (DVAX), NVIDIA (NVDA), Verastem (VSTM), Sorrento Therapeutics (SRNE) and TG Therapeutics (TGTX).

Vericel trades on the NASDAQ under the ticker symbol "VCEL."

Vericel's stock is owned by many different institutional and retail investors. Top institutional shareholders include Fort Washington Investment Advisors Inc. OH (1.55%), Summit Creek Advisors LLC (1.05%), Conestoga Capital Advisors LLC (0.22%), SG Americas Securities LLC (0.11%), Mesirow Financial Investment Management Inc. (0.04%) and Emerald Advisers LLC (0.04%). Company insiders that own Vericel stock include Dominick Colangelo, Gerard J Michel, Michael Halpin, Paul K Wotton and Steven C Gilman.
View institutional ownership trends for Vericel.

VCEL stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Emerald Advisers LLC, Falcon Point Capital LLC, Fort Washington Investment Advisors Inc. OH, Mesirow Financial Investment Management Inc., and SG Americas Securities LLC. Company insiders that have sold Vericel company stock in the last year include Dominick Colangelo, Gerard J Michel, and Michael Halpin.
View insider buying and selling activity for Vericel.

VCEL stock was purchased by a variety of institutional investors in the last quarter, including Summit Creek Advisors LLC, Conestoga Capital Advisors LLC, Dupont Capital Management Corp, and Raymond James Financial Services Advisors Inc..
View insider buying and selling activity for Vericel.

Shares of VCEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of VCEL stock can currently be purchased for approximately $17.19.

Vericel has a market capitalization of $775.44 million and generates $117.85 million in revenue each year. The biotechnology company earns $-9,660,000.00 in net income (profit) each year or $0.18 on an earnings per share basis. Vericel employs 216 workers across the globe.

The official website for Vericel is www.vcel.com.

Vericel's mailing address is 64 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-588-5555 or via email at [email protected]